Study Reveals No Dementia Risk Advantage for Overactive Bladder Drugs

A recent study involving over 830,000 adults indicates that β3 adrenergic agonists do not lower dementia risk compared to anticholinergic medications.

A
Aapla Nagpur Desk
14 Nov 2026, 6:34 PM IST · 2 min read
Source: Emjreviews
Study Reveals No Dementia Risk Advantage for Overactive Bladder Drugs
KEY TAKEAWAYS
1

No significant difference in dementia risk between β3 agonists and anticholinergics.

2

High-risk anticholinergics showed a lower dementia hazard than β3 agonists.

3

Longer exposure to anticholinergics was not linked to increased dementia incidence.

A comprehensive study has found that adults treated with β3 adrenergic agonists for overactive bladder (OAB) do not experience a reduced incidence of dementia compared to those prescribed anticholinergic medications. This research, which analyzed data from over 830,000 patients, challenges the prevailing notion that β3 agonists provide a cognitive safety advantage over their anticholinergic counterparts.

The study examined the dementia incidence among three groups of medications: high-risk anticholinergics, low-risk anticholinergics, and β3 adrenergic agonists. Researchers aimed to determine if prolonged exposure to anticholinergic drugs correlated with a heightened risk of developing dementia. The cohort comprised 830,393 adults aged between 40 and 90, all of whom began pharmacological treatment for OAB between 2012 and 2025, without any prior dementia diagnosis.

Among the participants, 70.5% were women, with a median age of 67. The medications were categorized into high-risk anticholinergics, such as oxybutynin and tolterodine, low-risk options like darifenacin and trospium, and β3 agonists including mirabegron. The study identified dementia cases through diagnostic codes and prescriptions for dementia-specific medications, employing advanced statistical methods to compare outcomes across the medication groups.

During the follow-up period, 65,134 patients developed dementia. Statistical adjustments revealed that high-risk anticholinergics had a lower dementia hazard compared to β3 agonists, with a hazard ratio of 0.90. Furthermore, high-risk anticholinergics also showed a lower hazard than low-risk anticholinergics. However, no significant difference was found between low-risk anticholinergics and β3 agonists.

The findings suggest that the 10-year dementia risk was highest among users of β3 agonists at 20.0%, compared to 18.1% for high-risk anticholinergic users. Although longer exposure to anticholinergics was not linked to increased dementia incidence, researchers noted that the differences observed between medication groups were modest and could be influenced by unmeasured confounding factors. The study concludes that β3 agonists do not offer a lower risk of dementia compared to anticholinergic medications, indicating that prior associations may reflect confounding rather than a direct pharmacological effect.

💬What did you think of this story?What did you think?

Read Next

No Dementia Risk Advantage for OAB Drugs